Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin and e-PROs for Radio-induced Breast Fibrosis
NCT04356209Phase 2Recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Jan 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pravastatin in radiation-induced fibrosis (RIF) (2 arms), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Benefit on breast-related quality of life of systematic e-PROs at 12 months. Started Jan 2020; status: recruiting.
02
Drugs
pravastatin
03
Conditions
radiation-induced fibrosis (RIF)
Beyond the preview
Go deeper on NCT04356209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356209.